Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 8, 2025American Journal of HematologyOpen Access

Efficacy and Thrombotic Risk of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia Secondary to Systemic Lupus and Antiphospholipid Syndrome: French Experience With 80 Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

CMCindy MarquesSorbonne UniversitéGMGuillaume MoulisUniversité Fédérale de Toulouse Midi-PyrénéesMRM. RoussotteHôpital de la Croix-Rousse

Discussion

Loading...

Member takes

Implication

Retrospective analysis reveals efficacy and varying thrombotic risks in immune thrombocytopenia associated with systemic lupus and antiphospholipid syndrome.

Key Points

  • TPO‐RAs showed an overall response of 78.8% for treating ITP in patients with systemic lupus and antiphospholipid syndrome.
  • Among 80 patients, 21 thrombotic events occurred, with a rate of 50% in the APS group compared to 8.1% in the SLE without APAs.
  • Patients with ITP associated with SLE can be treated effectively with TPO‐RAs, but careful monitoring for thrombotic risks is necessary.
  • Continuation of TPO‐RAs with anticoagulation resulted in a low risk of relapse for thrombotic events after initial occurrence.

Cite This Study

Marques et al. (2025) studied this question.

synapsesocial.com/papers/68e6494525bc5bdb98713c96https://doi.org/10.1002/ajh.70052
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 12019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus2019 · 2,668 citations
  2. 2The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France2024 · 6 citations